138 related articles for article (PubMed ID: 16010652)
1. The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory.
McKenna DH; Kadidlo DM; Miller JS; Orchard PJ; Wagner JE; McCullough J
Transfus Med Rev; 2005 Jul; 19(3):217-28. PubMed ID: 16010652
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease.
Harris DT; LoCascio J; Besencon FJ
Bone Marrow Transplant; 1994 Oct; 14(4):545-53. PubMed ID: 7858529
[TBL] [Abstract][Full Text] [Related]
3. [Umbilical cord blood as a source of stem cells].
Bojanić I; Golubić Cepulić B
Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
Shizuru JA; Jerabek L; Edwards CT; Weissman IL
Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
[TBL] [Abstract][Full Text] [Related]
6. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
7. Engineering hematopoietic grafts using elutriation and positive cell selection to reduce GVHD.
Noga SJ
Cancer Treat Res; 1999; 101():311-30. PubMed ID: 10800655
[TBL] [Abstract][Full Text] [Related]
8. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
10. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
11. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity.
Condiotti R; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185
[TBL] [Abstract][Full Text] [Related]
12. Umbilical cord blood transplantation--how, when and for whom?
Cohen Y; Nagler A
Blood Rev; 2004 Sep; 18(3):167-79. PubMed ID: 15183901
[TBL] [Abstract][Full Text] [Related]
13. Advances in umbilical cord blood cell therapy: the present and the future.
Berglund S; Magalhaes I; Gaballa A; Vanherberghen B; Uhlin M
Expert Opin Biol Ther; 2017 Jun; 17(6):691-699. PubMed ID: 28379044
[TBL] [Abstract][Full Text] [Related]
14. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
15. CD56
Kariminia A; Ivison S; Ng B; Rozmus J; Sung S; Varshney A; Aljurf M; Lachance S; Walker I; Toze C; Lipton J; Lee SJ; Szer J; Doocey R; Lewis I; Smith C; Chaudhri N; Levings MK; Broady R; Devins G; Szwajcer D; Foley R; Mostafavi S; Pavletic S; Wall DA; Couban S; Panzarella T; Schultz KR
Haematologica; 2017 Nov; 102(11):1936-1946. PubMed ID: 28935847
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
17. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
18. Stem cell bioengineering strategies to widen the therapeutic applications of haematopoietic stem/progenitor cells from umbilical cord blood.
Andrade PZ; dos Santos F; Cabral JM; da Silva CL
J Tissue Eng Regen Med; 2015 Sep; 9(9):988-1003. PubMed ID: 23564692
[TBL] [Abstract][Full Text] [Related]
19. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
